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Abstract   
Background/aims: Direct acting antivirals (DAA) provide an unprecedented 
opportunity for a  “find-and-treat strategy”. We aimed to report real-world clinical, 
patient reported and health economic outcomes of community-based HCV 
screening/treatment in people who use drugs (PWUD). 
Methods: Project ITTREAT (2013-2021), established at a drug and alcohol treatment 
centre, offered a comprehensive service. Generic (SF-12v2 and EQ-5D-5L) and liver-
specific (SFLDQoL) health related quality of life (HRQoL) were assessed before and 
after HCV treatment. Costs/case detected and cured were calculated. Primary 
outcome measure was sustained virological response (SVR) (intention to treat). 
Results: Till March 2018, 573 individuals recruited, 462 (81%) males, mean age 40.5 
+ 10.0 years. Of the 125 treated, 115 (92%) had past/current history of injecting drug 
use, 88 (70%) were receiving opioid agonist treatment and 50 (40%) were homeless. 
Twenty-six percent received interferon-based and 74% DAA-only regimens. SVR (ITT) 
was 87% (90% with DAAs). Service uptake/HCV treatment completion rates were > 
95%, HCV reinfection being 2.63/100 person years (95% CI 0.67-10.33). HRQoL 
improved significantly at end of treatment in those with SVR: SFLDQoL (symptoms, 
memory, distress, loneliness, hopelessness, sleep and stigma) (p</= 0.011); SF-12 v2 
physical and mental health domains (p<0.001); and EQ-5D-5L composite profile 
score (p= 0.009) and visual analogue scale, p<0.001. Cost (British pounds 2018) per 
case detected was £171; mean cost per cure (excluding medication) was £702 + 188. 
Conclusions: Excellent real-world SVRs in PWUD with significant improvement in 
HRQoL can be achieved at modest costs. Project ITTREAT endorses community-based 
integrated services to help achieve HCV elimination. 
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Lay Summary 
1. Despite the new oral antiviral medication, achieving hepatitis C virus (HCV) 
elimination will require engaging with people who use drugs. However, such 
individuals often do not attend hospital appointments.  
2. We describe a novel community-based model of care with all services being 
provided at a Drug and Alcohol Treatment Centre. 
3. We observed excellent service uptake. HCV cure rates were comparable to a 
hospital- based service with significant improvement in quality of life. This 
was achieved at modest costs. 















Globally, hepatitis C virus (HCV) infection is a major health burden affecting about 71 
million individuals (1). After the advent of direct acting antivirals (DAA) (2-6), the 
World Health Organisation (WHO) set ambitious targets to eliminate viral hepatitis 
by 2030 (1).  
 
In England almost all HCV treatment (84%) occurs in secondary care (7). Of the 
estimated 113,000 with chronic HCV infection (8), injecting drug use (IDU) is cited as 
a risk factor in 92% (9). This is a marginalised/disenfranchised cohort with 
suboptimal engagement with health services (10). Nationally, while 50% with HCV 
being diagnosed by 2020 has probably been achieved, substantial work is needed to 
reach the 90% WHO target (1,8). Low treatment uptake amongst people who use 
drugs (PWUD) (<5-25/1000) (11) is a key factor hindering reduction in HCV disease 
burden. PWUD thus remain an important HCV reservoir impeding elimination. 
 
A systematic review conducted for the National Institute for Health and Care 
Excellence in 2012 and 2017 found little published evidence of effectiveness for 
strategies to increase hepatitis case finding (12). The availability of DAA, however, 
provides an unprecedented opportunity for a paradigm shift in service delivery to a 
community “find and treat” strategy.  
 
Though recent clinical trials and a meta- analysis confirm safety and efficacy of DAAs 
in PWUD (13-15), this may not reflect real world outcomes (15). Additionally, while 
HCV cure results in improved health related quality of life (HRQoL) (16-17), there are 
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limited data in PWUD, a cohort with significant comorbidity (18). Finally, without 
community-based HCV treatment cost estimates, making a future case for such a 
model will be difficult.  
 
ITTREAT (Integrated Community-based Test - stage - TREAT) is a “one stop” HCV 
service set up at a large drug and alcohol treatment centre in South East England 
(19). Our aims were to collect real-world data relating to HCV screening and 
treatment and assess patient reported and health economic outcomes amongst 
those treated.  
 
Patients and methods 
Project ITTREAT, is an eight year study that commenced in December 2013 and here 
we present yearfour results (Dec 2013-Mar 2018). While clinical data is being 
collected throughout the study, an embedded study (Nov 2015-Mar 2018) included 
patient reported outcomes and a health economic analysis. Suppl file 1 shows the 
study design.   
 
Study inclusion criteria were all adults aged > 18 years attending the drug and 
alcohol treatment centre and willing and able to give informed consent. Exclusion 
criteria were unwilling to give informed consent. These individuals were still offered 
the service but their data were not collected.  
 
The ITTREAT service, as described previously (19), involved an experienced hepatitis 
nurse working full time at the drug and alcohol treatment centre offering clients 
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blood borne virus (BBV) testing using the finger prick dry blood spot test (DBS) (Alere 
toxicology, London, UK) (20). This allowed assessment of HCV antibody (if positive 
reflex HCV qualitative RNA), hepatitis B surface antigen, hepatitis B core antibody 
and HIV antibody (20) using the following assays: Biorad hepatitis C antibody (ELISA), 
Murex hepatitis B surface antigen (ELISA), Biorad hepatitis B core total antibody 




Those with a positive HCV qualitative RNA were called back to the drug and alcohol 
treatment centre and offered HCV quantitative RNA/genotype; clinical bloods; 
FibroScan®(402 Echosens); liver ultrasound and gastroscopy if cirrhotic (both 
performed at the local hospital) and HCV treatment assessment (Fig 1a). 
 
After completion of these assessments, and consultation with the Hepatologist if 
necessary, the Hepatitis nurse presented clients at the weekly hospital 
multidisciplinary meeting (MDM) for treatment decisions.  
 
DAAs became available in England in mid-2014 and HCV treatment is administrated 
via 22 national centers known as Operational Delivery networks (ODNs). DAA 
regimen was determined and funded by the National Health Service England (NHSE). 
Each ODN could only treat a pre-determined number of individuals per year. HCV 
treatment could be offered under exceptional criteria irrespective of fibrosis stage. 
This included PWUD who were eligible to receive DAA as a “window of opportunity” 
(21-22). Other barriers to HCV treatment included reluctance in treating PWUDs and 
 8 
restriction on the number of DBS tests that could be performed per year at the drug 
and alcohol treatment centre. Therefore restrictions were not all related to NHSE 
and or fibrosis stage. Restrictions did ease over the study period, with each ODN 
treating an increasing number with HCV per year. 
 
HCV treatment was delivered at the drug and alcohol treatment centre by the 
Hepatitis nurse under Hepatologist supervision. Clinics were “drop in”, with onsite 
psychiatric input, opioid agonist treatment (OAT), social/peer mentor support and a 
needle syringe programme. All those with a positive HCV RNA were deemed 
treatment eligible (irrespective of on going drug and alcohol use), unless not stable 
enough to engage and/or due to NHSE/other restrictions (deferred candidates, table 
1).  
 
Data collection  
All data were prospectively collected by the Hepatitis nurse. Clinical data were 
collected between Dec 2013 - Mar 2018 (demographic, service uptake, HCV 
treatment compliance and outcomes). Patient reported outcome measures (PROMs) 
were collected in consecutive individuals (from Nov 2015 to Mar 2018), at start (pre) 
and at end of (post) DAA treatment utilising the Short Form 12 Health Survey (SF-
12v2) (23), Short form liver disease quality of life (SFLDQoL) questionnaire (24) and 
EQ-5D-5L (25). Suppl file 2 provides details on how questionnaires were analysed 
and scored. Health economic data were collected from Nov 2015 to Mar 2018 in 
consecutive individuals undergoing DAA treatment. All steps in an individual’s care 
pathway (consultations, tests) from start of BBV screening to SVR testing were 
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recorded for inclusion in a micro costing exercise. Qualitative data have been 
reported separately (26). 
 
Outcome measures  
Primary outcome measure was intention to treat (ITT) sustained virological response 
(SVR)  (SVR12 or SVR24 depending on regimen). Secondary outcome measures 
included service uptake (BBV screening, fibroscan, HCV treatment), HCV treatment 
completion rates and compliance; reinfection; changes in PROMs (generic and 
specific health related quality of life [HRQoL]), pre and post HCV treatment in those 
achieving SVR, cost per HCV case detected and cost per HCV cure for all those 
receiving DAA and for whom PROMs data were also collected.  
 
Study definitions 
PWUD: any history of current or past drug use (injecting or non-injecting) and or 
those currently receiving OAT 
Current injecting and non-injecting drug use: use at time of HCV treatment initiation 
and or during HCV treatment. 
Current alcohol use: use at time of HCV treatment initiation and or during HCV 
treatment. 
Stability for HCV treatment: There were no strict definitions for stability. This was 
assessed on an individual basis by willingness and motivation to engage and be 
adherent with HCV treatment. Stability was determined, in the first instance by the 
Hepatitis nurse, in some cases with input from the clients themselves. In more 
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complex cases discussions were had with the Hepatologist, drug and alcohol team 
and colleagues at the Liver MDM.                     
SVR: absence of detectable virus (at any level) 12 or 24 weeks after end of treatment 
(EOT).  
Reinfection: any level of detectable virus after achievement of SVR. This was 
assessed 48-60 weeks post SVR as stipulated by NHSE. ODNs incurred financial 
penalties for failure to collect this data.  
Cirrhosis (Metavir F4): liver stiffness measurement (LSM) > 12 kPa (27-28). 
Homeless: street homeless/living in temporary accommodation.  
ITT analysis: Included all those commencing HCV treatment.  
Modified ITT (mITT) analysis: Excluded those lost to follow up after commencing HCV 
treatment.                                                                                                                             
 
Statistical analysis 
Clinical data (all those recruited from Dec 2013 – March 2018) 
Data are summarised using counts, means +standard deviations, medians 
(interquartile ranges [IQR]), or percentages. Student’s t-test and Chi-Square test 
were utilised for continuous and categorical variable respectively. Logistic regression 
analysis was used to model the relationship between the binary dependent 
outcomes (0 vs.1) treatment uptake (treated vs. deferred) and treatment outcome 
(SVR vs. non-SVR), and key independent factors (age, gender, IDU (current/past), , 
current non-IDU, alcohol use (current/past), current alcohol, use receiving OAT, 
homeless at initial assessment, any psychiatric diagnosis and fibrosis stage). A 
multivariate logistic regression model was then derived to look at the relationship 
 11 
between the key factors and the dependent outcome. To build the model, the 
statistically significant key factors from the bivariate analyses were added to the null 
model using forward selection where the factor with the highest significant p-value 
(p <0.05), based on the likelihood ratio test, was added next. Factors were removed 
from the model if p > 0.1. 
 
 HCV reinfection rate was calculated in those who had achieved SVR as the number 
of reinfections observed in the study period divided by the sum of all the years each 
individual was observed for multiplied by 100. The rate was presented per 100 
person years (PY).  
 
PROM analysis (consecutive individuals receiving HCV treatment from Nov 2015- 
Mar 2018)  
Differences in pre and post HCV treatment scores were calculated (mean + standard 
deviation) and compared using paired Student’s t-test. For each PROM, scores with 
<50% missing were imputed. Data were assumed to be missing at random. PROMS 
meeting the data completeness criteria were entered into the imputation model, 
which used chained equations, auxiliary variables (age, gender, whether current IDU 
and whether homeless at initial assessment) and 20 imputations (29). A sensitivity 
analysis was carried out by establishing whether the conclusions from the 
imputation model differed to those from a complete case analysis. For all statistical 




Health economic analysis                                                                                                            
A cost was attributed to staff time spent in consultations based on nationally 
validated rates, in British pounds 2018 (30).  Costs of tests were obtained from local 
financial managers.  
 
Cost per case detected was calculated as the total cost of all professional time and 
tests performed, involving all those invited to be screened, divided by the total 
number of individuals with a positive HCV qualitative RNA (a case), over the total 
study period (Dec 2013 to Mar 2018).  
 
To calculate the cost per cure of those receiving DAA (Nov 2015 to Mar 2018), the 
total cost of assessments and treatments was calculated at the individual level.  
Average costs were compared between those achieving SVR and those who did not, 
and between those receiving DAA + pegylated interferon vs. DAA-only regimens.  
Costs of medications, and time spent by the nurse in preparing documents, and 
presenting cases at the hospital MDM were not included. 
 
A macro level cost analysis was undertaken at the level of the service, based on the 
full economic cost of employing a nurse for a period of a year. 
 
Ethical approval for the study was obtained from NRES Committee East Midlands - 





Service uptake and case detection  
Table 1 shows baseline clinical and demographic data and service uptake, stratified 
by whether treated or HCV treatment deferred. Of the 558 tested, 259 (46%) were 
HCV qualitative RNA positive, this being significantly higher in those with history vs. 
no history of IDU (60% vs. 13%, p<0.001).  
 
Assessment  
The 259 with a positive HCV RNA underwent further assessment (Fig 1a and suppl Fig 
1) including a community based-fibroscan. Overall 47% (104/219) of those  
undergoing a fibroscan had >F2 fibrosis  and 24% (53/219) had cirrhosis. 
 
Treatment was deferred in 134/259 (53%) with a positive HCV RNA (table 1); 80 
(31%) were not stable enough and 54 (21%) due to NHSE and other restrictions. Of 
those stable to receive HCV treatment (n=179), 125 (70%) have been treated until 
March 2018. Table 2 shows bivariate and multivariate analysis of factors associated 
with receiving HCV treatment vs. treatment being deferred. Independent predictors 
of receiving treatment were absence of current IDU (OR 0.39, 95% CI 0.25-0.72, 
p=0.002) and absence of homelessness (OR 0.40, 95% CI 0.24-0.66, p=0.001).  
 
HCV treatment outcomes  
Table 1 shows baseline data in the 125 individuals who received HCV treatment. 
Prevalence of current IDU, alcohol use, receiving OAT and homelessness at initial 
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assessment were 34%, 26%, 70% and 40% respectively, genotype distribution (1 vs. 
3) was 45% vs. 49%. Just over a third (34%) had cirrhosis (table 1).  
 
Overall, 33/125 (26%) received interferon-based and 92 (74.0%) DAA-only regimens, 
(sofosbuvir-based in 48/92,52%) (suppl table 1). Overall, 71% (89/125) of the 
regimens contained ribavirin. From 2014-2016, 28 received DAA-only regimens 
(included 11% with F0-F1 fibrosis) but due to easing of NHSE and other restrictions, 
this increased to 64 from 2017-2018 (included 48% with F0-F1 fibrosis). 
 
On an ITT analysis SVR was 87% overall and 90% (83/92) in those receiving DAA-only 
regimens (fig 1b). Of the 16 with non-SVR, nine were true virological failures with 
seven (6%) being lost to follow (suppl table 1). Excluding these seven, on a mITT 
analysis, overall SVR was 92% and 95% in those receiving DAA-only regimens (Fig 1b).  
 
Table 3 shows demographic and clinical data in those with and without SVR. SVR was 
79% (34/43) if current IDU. Logistic regression of non-SVR was carried out on age, 
current IDU and treatment regimen (DAA-only vs. pegylated interferon/ribavirin + 
DAA). Insufficient data prevented statistical analyses of other variables. Current IDU 
was associated with an increased risk of non-SVR (OR=3.84, 95% CI 1.29-11.4, 
p=0.016). There was no association with age (OR=0.98, 95% CI 0.93-1.04; p=0.598) or 






In those individuals who were offered HCV treatment (n=125), uptake was 100% and  
treatment completion rate was 98% (122/125). Of the total of 406 community 
treatment clinic sessions, 96% (389) were attended. 
 
Reinfection  
Up to March 2018, of the 109 individuals achieving SVR, 76 have been retested, of  
whom two (3%) have developed HCV reinfection (2.63/100 PY, 95% CI 0.67-10.33). 
Both had IDU relapse. Reinfection data are currently unavailable in the remaining 33 
individuals.  
 
Patient reported outcome measures (PROM) 
During Dec 2015 to Mar 2018, 85 consecutive individuals were offered and accepted 
questionnaire-based assessments pre and post HCV treatment. Twelve received 
pegylated interferon/ribavirin + sofosbuvir and 73 DAAs-only, 61/85 (72%) of the 
regimens contained ribavirin. Of the 85, 78 (92%) achieved SVR. Of the seven not 
achieving SVR, five received DAA-only regimens and two pegylated interferon/ 
ribavirin + sofosbuvir. Of the 78 achieving SVR, 29% (23/78) were current IDUs, 27% 
(21/78) were current non-IDUs and 4% (3/78) were both current IDUs and non-IDUs. 
 
Two domains of SFLDQoL (sex and effect of liver disease) had >50% missing data and 
so were excluded from the imputation model and were only summarised using 
complete cases (sex n=8; effect of disease n= 17). Remaining PROMs had 18-22% pre 
– post scores missing and 303 imputations were made.  
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Figs 1c and 1d show the mean changes in SF-12v2 and SFLDQoL scores respectively, 
pre and post HCV treatment in the 78 who achieved SVR. Actual scores are shown in 
suppl table 2.  There were significant improvements (p<0.05) in all domains tested. 
Sensitivity analysis showed that there was no change in drawn conclusions as a 
result of multiple imputation following a complete case analysis (data not shown).  
Compared to baseline, there were also significant improvement in EQ-5D-5L scores 
at the end of HCV treatment: composite profile score 0.65 + 0.3 vs. 0.73 + 0.03, 
p=0.009 and VAS 52.79 + 2.04 vs. 72.89 + 1.59, p<0.001. 
 
Health economic outcomes  
Cost per case detected: During the full study period (Dec 2013 to March 2018) a 
total of 573 individuals were invited for screening of which 558 accepted and 323 
had positive HCV antibody. Of the 323 individuals with positive HCV antibody, 259 
had a positive qualitative HCV RNA, with a cost per case detected of £171 (table 4) 
 
Cost per cure: Data on service utilisation were collected from 85 individuals who 
received interferon + DAA  (n=12) or DAA-only regimens (n=73) between November 
2015 and March 2018. The consultations and tests received by this subgroup, and 
associated costs are shown in table 5. The overall mean cost per cure (excluding drug 
costs) was £702 + 188. Average costs were lower for individuals who did not achieve 
SVR and higher for those receiving interferon + DAA regimens. Costs broken down 
into the pre-treatment, treatment and follow up phases are shown in suppl table 3. 
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The annual cost of running the service, based on the full economic cost of a band 7 
nurse (inclusive of management and facilities overheads) was around £84,000 
(British pounds 2018).   
 
Discussion  
Our real-world prospective community HCV study in PWUD is novel as in addition to 
assessing SVR, it also provides data on patient reported and health economic 
outcomes. Our treated cohort had high prevalence of current/past IDU (92%) and 
alcohol (89%) use with 70% on OAT and 40% being homeless.  Despite this, service 
uptake and HCV treatment completion were close to 100% with an almost 90% SVR. 
Three validated and independent HRQoL indicators confirmed significant 
improvement in generic and liver specific HRQOL at end of HCV treatment, achieved 
at modest costs. Importantly, though initially funded by research grants, our 
favourable outcomes indicated sustainability, leading to the adoption of the service 
by the hospital trust.  
 
We attribute the success of ITTREAT to it being a “one-stop” integrated and non-
judgmental service, which helped mitigate against non-engagement, corroborated 
by our qualitative data (26) and a recent systematic review (31). The Hepatitis nurse 
effectively linked all the different components of the service. In contrast, prior to set 
up of ITTREAT, only 5% of individuals with HCV infection referred from our drug 
alcohol treatment centre attended their local hospital appointment, none eventually 
being treated (10).   
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Our data is consistent with a recent meta-analysis in PWUD (15) (approximately 50% 
of the studies being community –based), that reported treatment completion rates 
of ~97% with SVR amongst those on OAT and recent IDU/non-injecting use being 
90·7% (95% CI 88·5-93·0) and 87.7% (95% CI 84.2%-91.3%) respectively.  
 
Our community-based ITT SVR with DAAs (~90%) are similar to clinical trials involving 
PWUD (91.5%-94%) (13-14), but lower than that observed in non-PWUD clinical trials 
(4-5) and real world studies (96%- 99%) (3,6). However our mITT SVR (95%) are 
comparable suggesting that the apparently lower SVR in PWUD is probably due to 
loss to follow up rather than true virological failures. Our 6% loss to follow up 
(consistent with the aforementioned meta-analysis [15]) is indeed higher than that 
seen in non-PWUD real world studies and clinical trials (<1%) (4,6). A recent 
randomised controlled trial in PWUD on OAT, found higher SVR in those receiving 
group or directly observed treatment (94%-98%) compared with self-administered 
DAA therapy (90%). This highlights potential strategies for increasing treatment 
retention amongst PWUD (32). 
  
Our lowest SVR were seen in those with current IDU (79%). This is consistent with 
the Iceland TRAP C study (SVR 82%) (33), where even after accounting for the high 
(15%) dropouts, SVR was lower in those with IDU vs. no IDU in last six months  
(89.9% vs. 95.3%) (33). This should however not deter health care professionals from 
offering HCV treatment to people with recent IDU. Mathematical modelling suggests 
that with an 18 fold increase in HCV treatment (54/1000 PWUD/ year), and assuming 
a 90% SVR, HCV seroprevalence can be reduced by 75% (to <15% within 15 years). 
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An 80% SVR will only reduce impact by 12%-15%, still adequate for a treatment as 
prevention strategy (34). PWUD should therefore be a priority for scaling up HCV 
testing/treatment and linkage to care (15).  
 
Our HCV reinfection rate of 2.6/100 PY is supported by recent data (35-36). In Rossi 
et al’s study (36), reinfection amongst recent and former PWUD was 3.1/100 PYs 
(95% CI 1.9-23.5) and 1.4/100 PYs (95% CI 1.1-12.9) respectively, with only one 
individual receiving daily OAT developing reinfection. This reiterates the importance 
of on-going follow up of PWUD post SVR to ensure engagement with OAT services 
 
Earlier studies (summarised in two recent reviews [16-17]) report the severe HRQoL 
impairment with interferon-based treatments; persisting for up to 12 weeks post 
treatment irrespective of SVR. Ribavirin was also associated with modest but 
reversible impairment (16-17). DAA on the contrary significantly improve patient 
reported outcomes (irrespective of fibrosis stage), within the first month into 
treatment (16-17). Our study suggests that even in PWUD, a cohort with 
considerable comorbidity (18), successful DAA therapy results in significant 
improvements in generic and liver specific HRQOL. This could have also contributed 
to adherence. Therefore in PWUD, DAA associated virological cure results in benefits 
over and above that related to just the liver.  An Australian study reported that 
PWUD are seeking outcomes 'beyond cure' including improved physical and mental 
health and positive changes in identity and social relationships (37). 
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Our excellent outcomes in this hard-to-reach group have been achieved at modest 
cost (~ £880, at 2018 prices), when screening, assessment, and treatment were 
combined. Drug costs, which make up a large proportion of treatment costs were 
excluded since these vary depending on local negotiations, and are expected to fall 
over time.  Prior studies (38) have recorded higher costs per cure, even after 
medication costs were discounted. These studies, however, are not directly 
comparable with ours since they were based on the earlier treatment regimens 
where adverse events and treatment non-compliance were more common (38).  
 
Our study did have limitations. This community model of care was based at a single 
site in England, the trusting client provider relationship being the key to engagement 
(26). Since this may not be applicable to other geographical sites our study lacks 
generalisability and external validity to support a national change in service delivery. 
However, a recent systematic review, involving studies from multiple countries 
reporting different models of care reported excellent community-based SVR in 
PWUD (15).  
 
In conclusion Project ITTREAT endorses community-based integrated services.   
Excellent real-world SVR in PWUD can be achieved at modest costs with significant 
improvement in HRQoL after HCV cure. Such models of care could help pave the way 







Figure legends  
 
Fig 1a. Participant pathway (with numbers at each stage) 
Fig 1b. SVR in treated cohort 
Fig 1c. Mean (with SE bars) SF-12 scores pre and at end of (post) HCV treatment in 
those achieving SVR (n=78) 
Fig 1d. Mean (with SE bars) SFLDQoL scores pre and end of (post) HCV treatment in 
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Table 1 Baseline data in whole cohort and in those with a positive HCV RNA   
 
  HCV RNA positive n=259 
 Whole cohort 
(n=573) 





Age < 40 









































Current injecting drug use 
Yes 
No 









































Non Injecting drug use  
Current non injecting drug 
use 





























Alcohol use (current/past) 
Current alcohol use 










Homeless at initial 
assessment 
289 (50%) 79 (59%) 50 (40%) 
Receiving OAT 299 (52%) 96 (72%) 88 (70%) 






Uptake of BBV testing 
HBcAb positive 
HCV Ab positive  














































Viral load (iu/L) 
 
Viral load > 1.0 x 106  (iu/L) 
1.3 x 106+2.2 x 106  
  
89 (32%)  
1.2 x 106+1.9 x 106                                  
 
35 (29%) 
1.9 x 106+3.1 x 
106   
54 (43%)  
Comorbidity 147 (10%) 43 (32%) 51 (41%) 
 
Underwent fibroscan*   
F0-F1 (<7.1 kPa) 
F2-F3 ( > 7.1-11.9 kPa ) 























45.0 +5.4 [n=277] 
1 (0.1) [n=204) 
206.2 + 68.5 [n=232] 
7 (5) [n=104] 
55 (67) [n=104] 
45.4 +5.4 [n=104] 
1 (0.1) [n=61] 
228.3 + 70.5 [n=84] 
8 (6)  
57 (48) 
44.3 +4.8  
1 (0.1) 
190.9 + 63.6 
Received prior HCV 
treatment 
13 (2%)   2 (2%) 8 (6%)  
OAT Opioid agonist treatment  
* Reference no 27-28 
** Fibroscan unsuccessful in one 
Brackets [] indicate number with data available 





































Table 2. Bivariate and multivariate analysis of those who received HCV treatment vs. those in whom 
treatment was deferred 
 
 Bivariate analysis Multivariate analysis 
Key variables OR 
95% CI 
p-value OR 95% CI p-value 
Age (per year 
increase in age) 
1.05 (1.02, 1.07) 0.001    
Male 1.03 (0.54, 1.94) 0.943    
IDU (current/past) 1.04 (0.42, 2.53) 0.936    
Current IDU  0.39 (0.23, 0.66) <0.001 0.42 (0.25,0.72) 0.002 
Current non-IDU  0.69 (0.42, 1.15) 0.156    
Alcohol use 
(current/past) 
0.65 (0.28, 1.51) 0.313    
Currently drinking 
alcohol 
0.54 (0.33, 0.9) 0.018    
Receiving  OAT 0.63 (0.37, 1.06) 0.079    
Homeless at initial 
assessment 
0.40 (0.24, 0.66) <0.001 0.43 (0.26, 0.72) 0.001 
Any psychiatric 
diagnosis 
1.02 (0.62, 1.69) 0.939    
F2-F4 fibrosis  1.32 (0.81, 2.17) 0.260    




























Table 3 Baseline demographic and clinical data in those with SVR and non-SVR (n=125)  
 
  Non- SVR 
n = 16 
SVR    
n = 109 
Age (yrs) 
Age < 40 
















Injecting drug use (current/past) 
Current injecting drug use 
Injecting daily§ 









Current non injecting drug use 
Using daily** 







Alcohol use (current/past) 
Current alcohol use 




96 (88%)   
27 (25%) 
21 (19%) 
Homeless at initial assessment 6 (38%) 44 (40%) 
Receiving OAT 12 (75%) 76 (70%)  
Psychiatric diagnoses  10 (63%) 71 (65%) 
Genotype 1 
Genotype 3  
Viral load (VL) 







1.9x106 +3.2 x106 
45 (42%) 
Comorbidity 8 (50%) 43 (39%)  
Liver stiffness measurement  >12kPa 






























Note: §= proportion calculated out of the subset who report current drug/alcohol use; for continuous 
















Table 4. Cost per case detected for 573 individuals invited for blood borne virus screening 
 






Unit cost+ Cost 
per 
person 
Total cost £ 
2018 
Initial invitation for BBV screening 
screen by substance use worker 
5 minutes 573 £51/hour £4 £2435 
Initial consultation with nurse for  15 minutes 558 £53 £13 £7394 




558 £33++ £33 £18414 
Lab test qualitative HCV RNA (from 
same DBS if HCV antibody +ve) 
Not 
relevant 
323 £50 £50 £16150 
Number of cases (positive 
qualitative HCV RNA), cost per case, 
total screening costs 
 259   £171 £44,393 
+ Unit costs: Alcohol health worker/ liaison nurse/ substance misuse worker, Curtis and Burns 2018, page 
50; Band 7 nurse, Curtis and Burns 2018, page 119; costs of tests from local financial managers.  







Table 5 Cost per cure (British pounds, 2018) in 85 individuals receiving direct acting antivirals (excludes cost of drugs) 
Items of service use Number of tests and consultations1 Costs (£ 2018)6 
  Total Mean SD Min Max Mean SD Min Max 
Quantitative HCV  RNA2 253 3.0 0.2 2 3 207 10.6 139 208 
Full Blood Count(FBC)2 253 3.0 0.2 2 3 29 1.5 19 29 
Blood Renal Profile(U/E)2 253 3.0 0.2 2 3 13 0.7 9 13 
Blood Liver Function Test(LFT)2 253 3.0 0.2 2 3 16 0.8 11 17 
Nurse consultation brief (30 mins)3 513 6.0 2.5 2 17 160 66.1 53 451 
Nurse consultation (60 mins) 91 1.1 1.1 0 7 57 56.5 0 371 
Hepatologist review (30 mins) 10 0.1 0.3 0 1 6 17.5 0 54 
Nurse home visit (30 mins) 44 0.5 2.2 0 15 15 63.8 0 443 
Fibroscan4 84 1.0 0.1 0 1 124 13.6 0 125 
Liver ultrasound (hospital) 5 63 0.7 1.3 0 6 74 125.5 0 600 
Granulocyte colony stimulating factor Test (GSCF) 3 0.04 0.3 0 3 2 17.2 0 158 
Costs 85         702 188 456 1,349 
  
Subgroup comparisons N        Mean SD Min Max 
Achieved SVR 78 709 193.3 505 1349 
Did not achieve SVR 7 621 83.7 456 709 
DAA-only regimen 73 684 161.6 505 1136 
DAA with PEG INF 12 814 288.3 456 1349 
 SVR with DAA-only regimen  68 685 167.2 505 1136 
Non SVR with DAA-only 
regimen  
5 663 31.6 630 709 
SVR with DAA + PEG 
INF/RBV  regimen  
10 874 277.5 603 1349 
Non SVR with DAA + PEG 
INF/RBV regimen  
2 516 85.8 456 577 
1 Tests/consultations during three phases: pre-treatment, treatment, 12 or 24 weeks post treatment. One patient died just after completing HCV treatment 
 32 
2 Since blood test frequency changed during the study period, we assumed that all patients received one set of blood tests (Quantitative HCV RNA, FBC, U/E 
and LFT) in each of the three phases (as was the protocol at the end of the study). 
3 Consultations data missing for some patients so one 30 minute nurse consultation was assumed. 
4  Every patient except 1  received a Fibroscan pre-treatment. 
5  Only patients with F4 Fibrosis received ultrasounds pre-treatment, during treatment and during follow up. 
6 Unit costs: Costs of tests from the local financial manager: quantitative HCV RNA £69.41; FBC £9.58; U/E £4.32; LFT £5.50; Fibroscan £125; liver ultrasound 
£100; GCSF £52.70. Band 7 nurse £53 per hour, Curtis and Burns 2018, page 119 with £3 added for travel costs for home visits; Hepatologist £108 per hour, 
Curtis and Burns 2018, section 15. 
DAA direct acting antiviral, PEG INF pegylated interferon, RBV ribavirin 
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